Stock EVARF LOMBARD MEDICAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Lombard Medical, Inc.

Equities

EVARF

KYG555981094

Market Closed - OTC Markets
Other stock markets
 01:10:00 29/11/2023 GMT 		5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for Lombard Medical, Inc. -.--% -.--%
2017 Lombard Medical, Inc.(NasdaqCM:EVAR) dropped from NASDAQ Composite Index CI
2017 Lombard Medical, Inc. Announces Unaudited Earnings Results for the Third Quarter Ended September 30, 2017; Provides Earnings Guidance for the Fourth Quarter of 2017 and Fiscal Year 2018 CI

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lombard Medical, Inc. Announces Unaudited Earnings Results for the Third Quarter Ended September 30, 2017; Provides Earnings Guidance for the Fourth Quarter of 2017 and Fiscal Year 2018
CI
Lombard Medical, Inc. Announces Full Commercial Launch of Japan of its New Low-Profile IntelliFlex LP Delivery System for the Aorfix AAA System
CI
Lombard Medical, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Reports Impairment-Goodwill and Long-Lived Intangibles for the Fourth Quarter of 2016
CI
Lombard Medical, Inc. and MicroPort Scientific Corporation Finalize Strategic Partnership Agreements
CI
Lombard Medical, Inc. and MicroPort Scientific Corporation Announce Strategic Partnership
CI
Lombard Medical, Inc. Announces Positive Long-Term Data for Aorfix™
CI
Lombard Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016
CI
Lombard Medical, Inc. Wins GBP 202.7 Million Multiple Awardees Contract
CI
Lombard Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016
CI
Lombard Medical, Inc. Announces CE Mark Approval for IntelliFlex™ LP Delivery System for the Aorfix™ Abdominal Aortic Aneurysm Endovascular Stent Graft
CI
Lombard Medical, Inc. Plans to Conduct 1,000 Patient Global Registry to Evaluate New Altura Endograft System
CI
Lombard Medical, Inc. Announces Positive Clinical Results from The Prospective Aneurysm Trial
CI
Lombard Medical Receives Australian Therapeutic Goods Administration Approval for the Aorfix Endovascular Stent Graft for the Treatment of Abdominal Aortic Aneurysms
CI
Lombard Medical, Inc. Announces Consolidated Unaudited Financial Results for the First Quarter Ended March 31, 2016; Provides Revenue Guidance for the Year 2016
CI
Lombard Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015; Provides Revenue Guidance for 2016
CI
Lombard Medical, Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2015; Announces Launch of Altura Aaa Product Line and Aorfix Intelliflex LP Delivery System
CI
Lombard Medical, Inc. Presents Efficacy and Safety Data from the Three-Year Follow up of the U.S. PYTHAGORAS Pre-Marketing Approval Trial of Aorfix
CI
Lombard Medical Announces Positive Results of First-in-Man Clinical Case Using New Low Profile IntelliFlex LP Delivery System to Deploy Aorfix Endovascular Stent Graft
CI
Lombard Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Reaffirms Revenue Guidance for the Year 2015
CI
Lombard Medical, Inc. acquired Altura Medical, Inc. from New Leaf Venture Partners, L.L.C., Advanced Technology Ventures, SV Life Sciences Fund IV, backed by SV Life Sciences Advisers, LLC and others for $49 million.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. EVARF Stock
  4. News Lombard Medical, Inc.
  5. Highlights